Chemicals & Small Molecules

Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of the human microtubule-associated protein tau and targets tau protein by binding to amino acid residues at the N-terminal end of tau protein. Tilavonemab blocks the ability of human and mouse neurons to uptake tau aggregates and can be used to study neurological diseases.

Olokizumab (CDP-6038) is a humanized anti-IL-6 monoclonal antibody that selectively blocks the final assembly of the IL-6 signaling complex for the study of rheumatoid arthritis (RA).

Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway. It has antitumor activity, inhibits tumor cell proliferation, and can be used in the study of leukemias and lymphomas.

Intetumumab (CNTO 95) is a fully human anti-α(v)-integrin monoclonal antibody that is a radiosensitizer in xenograft tumor-bearing mice, inhibits tumor growth, and reduces lung metastases in the A549 NSCLC xenograft model.

Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity for the study of advanced HER3-positive solid tumors and breast cancer.

Ruplizumab (BG 9588) is a humanized IgG1κ-like monoclonal antibody against CD40L. Ruplizumab is used in the study of neurological and immune system disorders.

Lirentelimab (AK002) is a humanized anti-sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) antibody that induces apoptosis of IL-5-activated eosinophils and inhibits IL-5-mediated mast cell activation, and is used in the study of refractory inert systemic mastocytosis and allergic conjunctivitis.

Volagidemab (AMG-477) is a glucagon receptor (GCGR) antagonist and monoclonal antibody for the study of endocrine and metabolic diseases such as type 1 diabetes (T1D) and hypoglycemia.

Vesencumab (MNRP-1685A) is an IG1 antibody targeting NRP-1 with anti-angiogenic and anti-tumor activity that reduces the number of globules formed by the SUM159 and Hs578T cell lines. Vesencumab inhibits EGFR and PDGFRα activation and can be used to study solid tumors.